"Carboplatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An organoplatinum compound that possesses antineoplastic activity.
| Descriptor ID |
D016190
|
| MeSH Number(s) |
D02.691.800.338
|
| Concept/Terms |
Carboplatin- Carboplatin
- cis-Diammine(cyclobutanedicarboxylato)platinum II
- CBDCA
|
Below are MeSH descriptors whose meaning is more general than "Carboplatin".
Below are MeSH descriptors whose meaning is more specific than "Carboplatin".
This graph shows the total number of publications written about "Carboplatin" by people in this website by year, and whether "Carboplatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 5 | 6 |
| 2004 | 0 | 3 | 3 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 4 | 4 |
| 2007 | 1 | 4 | 5 |
| 2008 | 1 | 11 | 12 |
| 2009 | 1 | 6 | 7 |
| 2010 | 1 | 5 | 6 |
| 2011 | 4 | 15 | 19 |
| 2012 | 4 | 3 | 7 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 5 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 3 | 2 | 5 |
| 2018 | 0 | 9 | 9 |
| 2019 | 1 | 8 | 9 |
| 2020 | 1 | 4 | 5 |
| 2021 | 4 | 7 | 11 |
| 2022 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carboplatin" by people in Profiles.
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
-
Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide. J Thorac Oncol. 2022 09; 17(9):1122-1129.
-
CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022 04 20; 40(12):1323-1334.
-
Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. BMC Cancer. 2022 Jan 03; 22(1):17.
-
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 11; 27(11):1910-1920.
-
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens. Int J Cancer. 2022 01 15; 150(2):279-289.
-
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. J Clin Oncol. 2021 11 10; 39(32):3633-3644.
-
GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. Clin Cancer Res. 2021 10 15; 27(20):5536-5545.
-
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. Lung Cancer. 2021 09; 159:56-65.
-
Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. Gynecol Oncol. 2021 08; 162(2):375-381.